Core Insights - The report highlights that in 2024, the total salary of A-share listed company secretaries reached 4.086 billion yuan, with an average annual salary of 754,300 yuan [1] - A total of 1,144 company secretaries earned over 1 million yuan, accounting for more than 21% of the total [1] Salary Distribution - The average annual salary for company secretaries in the medical and healthcare services sector is 839,200 yuan [2] - The distribution of salaries shows that 24% earn below 500,000 yuan, 48% earn between 500,000 and 1 million yuan, and 28% earn above 1 million yuan [2] - The top three highest-paid company secretaries are Gilbert Shing Chung Li from Kanglong Chemical with 1.9855 million yuan, Gao Dapeng from Zhaoyan New Drug with 1.7384 million yuan, and Xu Xiangke from Kailaiying with 1.6114 million yuan [2] Age and Education Distribution - Company secretaries aged 40 and below constitute 43% of the market, while those aged 50 and above account for 22% [1] - The educational background of company secretaries shows that 34% hold a bachelor's degree, 52% have a master's degree, and 14% possess a doctoral degree [1] - Among the doctoral degree holders, there are 7 individuals, with the only full-time doctoral company secretary in the industry being Cao Nai'en from Huaxia Eye Hospital [1]

Group 1 - The high-pressure oxygen chamber concept increased by 2.56%, ranking third among concept sectors, with five stocks rising, including Innovation Medical which hit the daily limit, and others like BeiYikang, Jinling Pharmaceutical, and Yingkang Life showing gains of 17.75%, 3.79%, and 1.25% respectively [1][2] - The main funds net inflow into the high-pressure oxygen chamber concept was 239 million yuan, with Innovation Medical receiving the highest net inflow of 226 million yuan, followed by Jinling Pharmaceutical and Yingkang Life with net inflows of 41.83 million yuan and 6.52 million yuan respectively [2][3] - The net inflow ratios for Innovation Medical, Jinling Pharmaceutical, and Yingkang Life were 11.04%, 8.08%, and 4.30% respectively, indicating strong investor interest in these stocks [3] Group 2 - The top gainers in the high-pressure oxygen chamber concept included Innovation Medical, Jinling Pharmaceutical, and Yingkang Life, while the top losers were Weiao Co., Samsung Medical, and Tiejian Heavy Industry, with declines of 1.74%, 0.92%, and 0.69% respectively [1][4] - The trading volume and turnover rates for the leading stocks in the high-pressure oxygen chamber concept were significant, with Innovation Medical showing a turnover rate of 30.10% and a trading volume of 22.62 million yuan [3]

证券日报网讯盈康生命（300143）8月6日在互动平台回答投资者提问时表示，截至2025年7月31日，公 司股东总数为18，891户。 ...

Group 1 - The high-pressure oxygen chamber concept increased by 1.76%, ranking 7th among concept sectors, with 7 stocks rising, including Innovation Medical which hit the daily limit, and others like Beiyikang and Weiao Shares rising by 7.40%, 2.86%, and 0.74% respectively [1][2] - The concept sector saw a net inflow of 262 million yuan, with Innovation Medical receiving the highest net inflow of 472 million yuan, followed by Weiao Shares and Yingkang Life with net inflows of 3.37 million yuan and 769,200 yuan respectively [2][3] - The main capital inflow ratios for Innovation Medical, Weiao Shares, and Yingkang Life were 28.82%, 4.53%, and 0.85% respectively, indicating strong investor interest in these stocks [3] Group 2 - The top gainers in the high-pressure oxygen chamber concept included Innovation Medical with a daily increase of 10.03% and a turnover rate of 25.23%, while other stocks like Weiao Shares and Yingkang Life had increases of 2.86% and 0.68% respectively [3] - Conversely, stocks such as Tiedian Heavy Industry, Samsung Medical, and Jinling Pharmaceutical experienced declines of 1.50%, 0.70%, and 0.41% respectively, indicating a mixed performance within the sector [1][4]

Group 1 - The core point of the article is that Yingkang Life announced the approval of a proposal to use reserve funds to cover losses during the second extraordinary general meeting of shareholders in 2025 [2] Group 2 - The company held its second extraordinary general meeting of shareholders on August 1 [2] - The proposal to use reserve funds for loss compensation was successfully passed [2]

证券代码：300143 证券简称：盈康生命 公告编号：2025-036 盈康生命科技股份有限公司 2025 年第二次临时股东会决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记 载、误导性陈述或重大遗漏。 特别提示： 1、本次股东会未出现否决议案的情形。 2025 年 8 月 1 日 9:15-15:00。 2、本次股东会未涉及变更以往股东会已通过决议的情况。 一、会议召开和出席的情况 （一）会议召开情况 1、盈康生命科技股份有限公司（以下简称"公司"）2025 年第二次临时股东会 通知已于 2025 年 7 月 17 日以公告的形式向全体股东发出。具体内容详见公司刊登 于巨潮资讯网（www.cninfo.com.cn）的相关公告。 2、召开时间：现场会议召开时间为 2025 年 8 月 1 日（星期五）14:30。 （1）通过深圳证券交易所交易系统投票 2025 年 8 月 1 日 9:15-9:25，9:30-11:30 和 13:00-15:00； （2）通过深圳证券交易所互联网投票系统投票 3、会议召开地点：山东省青岛市崂山区海尔路一号盈康一生大厦董事会议室。 4、会议召开 ...

1. 经公司 2025 年第一次临时股东大会审议通过的《公司章程》； 2. 公司 2025 年 7 月 17 日刊登于巨潮资讯网及深圳证券交易所网站的《盈 康生命科技股份有限公司第六届董事会第十九次（临时）会议决议公告》； 3. 公司 2025 年 7 月 17 日刊登于巨潮资讯网及深圳证券交易所网站的《盈 康生命科技股份有限公司关于召开 2025 年第二次临时股东会的通知》 （以下简称《股东会通知》）； 4. 公司本次股东会股权登记日的股东名册； 北京市金杜（青岛）律师事务所 关于盈康生命科技股份有限公司 2025 年第二次临时股东会之 法律意见书 致：盈康生命科技股份有限公司 北京市金杜（青岛）律师事务所（以下简称本所）接受盈康生命科技股份 有限公司（以下简称公司）委托，根据《中华人民共和国证券法》（以下简称《证 券法》）、《中华人民共和国公司法》（以下简称《公司法》）、中国证券监督管理 委员会《上市公司股东会规则》（以下简称《股东会规则》）等中华人民共和国 境内（以下简称中国境内，为本法律意见书之目的，不包括中国香港特别行政 区、中国澳门特别行政区和中国台湾省）现行有效的法律、行政法规、规章、 规范性文 ...

证券代码：300143 证券简称：盈康生命 公告编号：2025-037 及相关凭证要求公司清偿债务或提供相应担保。债权人未在规定期限内行使上述权 利的，不会因此影响其债权的有效性，相关债务（义务）将由公司根据原债权文件 的约定继续履行。 债权人可采用现场、邮寄等方式进行债权申报，具体方式如下： 1、申报时间：2025 年 8 月 2 日起 45 日内，9:30-11:30，13:30-16:30（双休日 及法定节假日除外） 盈康生命科技股份有限公司 关于使用公积金弥补亏损通知债权人的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记 载、误导性陈述或重大遗漏。 一、通知债权人的原因 盈康生命科技股份有限公司（以下简称"公司"）于2025年7月16日召开第六 届董事会第十九次（临时）会议、2025年8月1日召开2025年第二次临时股东会，审 议通过了《关于公司使用公积金弥补亏损的议案》。具体内容详见公司于2025年7 月17日在巨潮资讯网（www.cninfo.com.cn）披露的《关于公司使用公积金弥补亏 损的公告》。 根据和信会计师事务所（特殊普通合伙）出具的和信审字（2025）第0 ...

| 交易日期 | 证券代码 | 证券简称 | 成交价格 | 成交量 | 成交金额 | 买方营业部 | 卖方营业部 | | --- | --- | --- | --- | --- | --- | --- | --- | | | | | (元) | (万股/万份) | (万元) | | | | 2025-07-29 | 300143 | 盈康生命 | 9.90 | 145.42 | 1,439.66 华福证券有限责任 | | 华福证券有限责任 | | | | | | | | 公司东莞东莞大道 | 公司东莞东莞大道 | | | | | | | 证券营业部 | | 证券营业部 | 7月29日，盈康生命大宗交易成交145.42万股，成交额1439.66万元，占当日总成交额的12.87%，成交价9.9元，较市场收盘价 10.13元折价2.27%。 ...

Core Viewpoint - Yingkang Life has been awarded the "ESG Corporate Governance Pioneer Award" for its outstanding practices in environmental, social, and governance (ESG) areas, highlighting its commitment to integrating economic efficiency with social responsibility [1][4]. Governance - Yingkang Life emphasizes robust corporate governance as the foundation for sustainable development and social responsibility, showcasing a well-structured governance framework led by the board of directors and supported by various committees [4]. - The company has a diverse and professional governance structure, with female board members making up 28.57% and three independent directors, enhancing decision-making and oversight [4]. - A unique "five-in-one" risk management framework has been established to systematically identify and respond to multiple risks, including climate change and medical quality safety [4]. Innovation and Quality - The governance system supports technological innovation and improvement in medical quality, with a 2024 R&D investment of 54.52 million yuan, representing 3.50% of revenue [5]. - The company launched innovative projects such as a "multimodal medical imaging AI platform," significantly improving diagnostic efficiency and accuracy, with a total outpatient volume of 496,700 and a customer satisfaction rate of 99.12% [5]. Environmental Responsibility - Yingkang Life actively promotes "green healthcare," with an annual environmental investment of 4.4 million yuan and clear energy-saving and emission reduction targets, achieving a greenhouse gas emission intensity of 5.57 tons CO2e per million revenue [5]. - The company’s second phase of the Guangci Hospital project employs advanced energy-saving technologies, achieving a 10% energy-saving rate [5]. Social Responsibility - The company focuses on creating a "happy workplace," providing 2,207 jobs with a female employee ratio of 66.11% and hiring nine disabled individuals [6]. - Employee development is prioritized, with a 100% training coverage rate and an average training duration of 48.15 hours per employee, alongside various employee welfare activities [6]. Recognition and Future Outlook - Yingkang Life has received high ESG ratings, including a score of 55 from S&P Global CSA and an AA rating from Wind ESG, ranking first in its industry [6]. - The company aims to deepen governance reforms, enhance risk management, accelerate medical technology innovation, and expand public welfare services by 2025, striving to become a global benchmark for sustainable development in the healthcare sector [6].